Related Experiment Video

Updated: Feb 10, 2026

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

6.9K

Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During

James L Januzzi1, Javed Butler2, Emmanuel Fombu3

  • 1Massachusetts General Hospital, Boston, MA; Baim Institute for Clinical Research, Boston, MA.

American Heart Journal
|May 15, 2018
PubMed

Insights

This study investigated how biomarkers change during sacubitril/valsartan treatment for heart failure with reduced ejection fraction. Understanding these biomarker shifts offers insights into the drug

Area of Science:

  • Cardiology
  • Pharmacology
  • Biomarker Research

Background:

  • Sacubitril/valsartan is a key treatment for heart failure with reduced ejection fraction (HFrEF).
  • The precise mechanism by which sacubitril/valsartan benefits patients is not fully understood.
  • Biomarkers related to cardiac remodeling, injury, and fibrosis may elucidate its mechanism of action.

Purpose of the Study:

  • To correlate changes in biomarkers with cardiac remodeling, cardiovascular outcomes, and patient-reported outcomes.
  • To assess short- and long-term alterations in biomarker concentrations linked to sacubitril/valsartan's effects.
  • To provide clinical guidance on interpreting biomarker data during HFrEF treatment.

Main Methods:

  • A 52-week, multicenter, open-label, single-arm study involving approximately 830 HFrEF patients.
  • Patients initiated and titrated on sacubitril/valsartan per US prescribing information.
  • Primary endpoints: changes in N-terminal pro-B-type natriuretic peptide and cardiac remodeling from baseline to 1 year.

Main Results:

  • The study is ongoing; results are pending.
  • Analysis will include changes in N-terminal pro-B-type natriuretic peptide and cardiac remodeling at 6 months and 1 year.
  • Exploratory endpoints will assess biomarker changes relative to cardiovascular events.

Conclusions:

  • The Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF) aims to clarify the mechanistic benefits of sacubitril/valsartan.
  • Findings will enhance understanding of angiotensin receptor-neprilysin inhibitor therapy.
  • Results will guide clinicians in utilizing biomarker information for HFrEF management.
Abstract

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.7K
Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

11.1K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
391
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
993
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
947
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
356